Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Superinvestors holding DMRA, Q2 2026
1 superinvestor reports holding Damora Therapeutics, Inc. on Form 13F, worth $60.1M in total. Weight is Damora Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Viking Global InvestorsAndreas Halvorsen | 0.2% | 2,311,082 | $60.1M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of DMRA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
1 superinvestor holding at quarter end
Q3 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q2 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−26.2%)